Norges Bank Crinetics Pharmaceuticals, Inc. Transaction History

Norges Bank

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2024	BUY	$15.73 - $23.6 $2.35 Million - $3.52 Million	149,100 New	149,100 $2.69 Million
Q1 2023 May 15, 2024	BUY	$15.31 - $21.1 $2.28 Million - $3.15 Million	149,100 New	149,100 $2.39 Million
Q1 2022 May 12, 2023	BUY	$17.15 - $28.31 $439,039 - $724,736	25,600 New	25,600 $561,000
Q1 2022 May 09, 2022	SELL	$17.15 - $28.31 $809,479 - $1.34 Million	-47,200 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$19.35 - $28.41 $913,320 - $1.34 Million	47,200 New	47,200 $1.34 Million
Q3 2021 Nov 14, 2022	BUY	$16.88 - $25.23 $364,608 - $544,968	21,600 New	21,600 $455,000
Q3 2021 Nov 05, 2021	SELL	$16.88 - $25.23 $1.23 Million - $1.84 Million	-72,800 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$15.9 - $21.15 $1.16 Million - $1.54 Million	72,800 New	72,800 $1.37 Million
Q2 2021 Aug 10, 2021	SELL	$15.9 - $21.15 $534,240 - $710,640	-33,600 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$13.3 - $17.55 $446,880 - $589,680	33,600 New	33,600 $513,000

241

79.6M

23.3K

44.3K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.94B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.